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ABSTRACT: 
 
Background and Objectives 
The purpose of this study was to assess the presence of birth cohort effects by exploring 
differences in established risk factors of Alzheimer’s disease (AD) and dementia using case-
control designs and also estimate the AD risk among women with respect to their number of 
biological children. 
Methods: This is a case control study design of participants born in 1896 – 1955 and were 
enrolled in one of the designated Alzheimer’s disease centers (ADCs). The uniform Data Set of 
the National Alzheimer’s Coordinating center (NACC) include those who had Alzheimer’s 
disease or mild cognitive impairment (cases) and were compared with those who were 
cognitively (controls) normal using multivariable logistic regression. The study sample was sub-
divided into five birth cohorts based on historical periods described above. Specifically, cohorts 
were constructed for the period leading up and through the end of WWI, Post WWI/the Roaring 
20s, Great Depression/Pre WWII, WWII, and Baby Boom Cohort. 
Results: Of all the participants enrolled in the ADC UDS and who were born between 1896 and 
1955, a total of 22,952 subjects, 12,702 (55.34%) were with AD or MCI and 10,250 (44.66%) 
were normal controls. Univariate and multivariable logistic regression analyses were performed 
and the frequency distributions, adjusted odds ratios (ORs), and corresponding 95% confidence 
intervals (95% CIs) were reported. Females accounted for the majority of participants in all birth 
cohorts at approximately or exceeding 60%, the Baby Boom (Birth Cohort 5) were youngest at 
baseline, had the least mean number of children, and highest level of education. After adjusting 
for all the covariates in the model, age, education, gender and race were seen to be associated 
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with AD and in addition to active smoking, hypertension and diabetes were observed to have 
variations in the point estimates for cohort-specific risk factors when compared with the overall 
estimate indicating the evidence of cohort effects. 
Conclusion: Evidence of cohort effect was observed in our study as the estimates of risk factors 
differed among the historically defined birth cohorts. Knowledge of cohort effects is very useful 
in predicting future trends of AD and dementia and the results from this analysis may strengthen 
the validity of future studies by informing discussions regarding cohort effects as a threat to 
epidemiologic investigations 
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ABBREVIATIONS: 
AD  Alzheimer’s disease 
MCI  Mild Cognitive Impairment 
MMSE  Mini Mental State Examination 
NACC  National Alzheimer’s Coordinating Center 
NIA   National Institute on Aging 
WWI  First World War 
WWII   Second World War 
APOE-4 Apolipoprotein epsilon 4 
DSM  Diagnostic and Statistical Manual of Mental Disorder 
UDS  Uniform Data Set 
PAR  Population Attributable Risk 
OR  Odds Ratio 
SAS  Statistical Analysis System 
IRB  Institutional Review Board 
FOAD  Fetal Origin of Adult Disease 
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INTRODUCTION: 
Overview of Alzheimer’s Disease: 
In the “2015 Alzheimer’s disease Facts and Figures,” the Alzheimer’s Association reported a 
prevalence of about 5.3 million Americans with Alzheimer’s disease (AD), out of which 5.1 
million (11%) are 65 years and above.1 Current estimates show that at least one person develops 
AD in the United States every 67 seconds.1 AD is presently the sixth leading cause of death in 
the United States (fifth largest cause for those who are 65 and above) with about 500,000 deaths 
attributable to AD in 2010 with accompanying high level of morbidity.1 According to several 
studies, the current estimate of AD burden indicates that there are approximately 33.9 million 
individuals worldwide with AD, and this estimate is projected to triple within the next 40 years 
as a result of longer life expectancies and demographic changes.2,3 The incidence rate of AD 
among those aged at least 85 years stands at about 15 – 30 percent, and this is expected to 
quadruple by the year 2040 leaving at least 1 in every 45 Americans affected.4 Available data 
shows an estimated 14 percent increase in the number of people with AD in every state of the 
nation.1 Survival times among AD patients 65 years and above have been observed to be 4 to 8 
years on average, with some evidence of up to 20 years seen in some patients; patients spend up 
to 40 percent of their illness in the most severe stage of the disease.1 AD is now categorized as 
the disease with the highest level of burden, measured by disability adjusted life years, in the 
United States.1  
The disease comprises three stages including the preclinical (or asymptomatic) phase of AD, 
mild cognitive impairment (MCI), and dementia.1 Dementia is characterized by several 
conditions including decline in memory and language, loss of ability to solve problems and other 
cognitive skills, including common daily activities.1 AD has been implicated as the most 
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common dementing disease or condition, accounting for about 60 – 80 percent of all cases of 
dementia.1 The disease occurs as a result of degeneration of the brain nerve cells (neurons) 
responsible for daily cognitive and body functions, eventually causing the individuals to be bed-
bound; end-stage patients are more vulnerable to several infectious diseases like pneumonia.1 
In addition to the burden on patients, family caregivers have been observed to be at a higher risk 
of emotionally related health problems when compared to non-caregivers.5 Likewise, the 
accompanying stress endured by family members as a result of caregiving is an independent risk 
factor for mortality, especially for the spouses.6 Informal caregiving by family resulted in an 
estimated 18 billion hours of unpaid service rendered to individuals with AD in 2014 alone.1 
Costs of care reached $226 billion in 2015 alone as a result of AD and other dementia.1 
Efforts towards the treatment of Alzheimer’s disease have not shown appreciable impacts to 
either prevent or slow disease progression.4,7 The available medications do not alter disease 
progression, and the treatments only produce a small effect on cognitive symptoms in 
individuals2 and generally fail to slow or stop the resulting symptoms of the disease.1 No 
treatment to date has shown effectiveness in altering the damage to the neurons,1 and efforts in 
the research of new medications for treatment have been hampered by failure in clinical trials.2 
For instance, available evidence show that between the years 2002 and 2012, there were 244 
drugs that were tested for AD in clinical trials and only one passed approval.1  Researchers 
however believe that early detection and treatment during the preclinical phase could play a 
major role in preventing, reducing the overall impact, or a complete halt in the progression of the 
disease.1 
Effective preventive approaches towards AD could be in the form of delaying the manifestation 
of symptoms,4 which develop only after several years or even decades.2 Barnes et al.2 also 
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reported that a delay in symptoms of at least one year could lead to a 9 million decrease in the 
number of AD cases over the next 40 years. And, there may be some good news on the horizon, 
Recent studies of AD incidence and prevalence have suggested that incidence of AD may 
actually be decreasing as healthier and more highly educated birth cohorts of adults move into 
old age. For instance, a dementia incidence study found that age-adjusted incidence and 
mortality were lower in the cohort of participants observed recently compared to the ones 
observed 10 years earlier.8 
 
Objectives: 
Cohort effects are a common problem that epidemiological studies face, especially those that 
employ longitudinal data collection, because the effect of the risk factors may not be uniformly 
distributed across all age groups at all points in time. The primary aim of the current study was to 
assess the presence of birth cohort effects by exploring differences in established risk factors of 
Alzheimer’s disease and dementia using case-control designs. In a secondary aim, we also 
examined AD risk among women with respect to their number of biological children. The 
sample is a convenience sample drawn from the National Alzheimer’s Coordinating Center 
(NACC), which aggregates standardized data elements collected by all federally-funded 
Alzheimer’s Disease Centers. The results from this analysis may strengthen the validity of future 
studies by informing discussions regarding cohort effects as a threat to epidemiologic 
investigations. 
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LITERATURE REVIEW: 
Alzheimer’s Disease Risk Factors: 
AD is regarded as a multifactorial disease,1,2,9 and some potential risk factors have been 
successfully identified using observational studies including hypertension, diabetes, smoking, 
which are regarded as vascular risk factors and are highly modifiable2,9,10 Other risk factors 
include age, race, apolipoprotein epsilon 4 (APOE-4), gender, and education.1,7,11 Vascular risk 
factors have been shown to increase the risk of dementia,8 and the impacts were shown to be 
greater when acting together than their individual effects acting alone.10 Reitz et al.4 have 
successfully carried out prediction of dementia using a risk score generated by these already 
established AD risk factors, and such methods are useful approaches towards prevention for 
those at risk. Risk prediction has proven to be useful in several other conditions including stroke, 
cardiovascular events, and diabetes.4 Risk factor modification, which examines the extent to 
which an intervention can either prevent or delay cognitive decline, has also been observed to 
have some considerable impacts in a few randomized controlled trials.12  
Diabetes mellitus has been observed to increase the risk of AD and dementia based on 
epidemiological studies.9,13 The global prevalence of diabetes was estimated to be 6.4% for the 
year 2010, and this represents about 285 million adults with diabetes worldwide; prevalence was 
shown to be highest in North America, with about 10.2%, and lowest in Africa with about 3.8%.2 
Based on the concept of PAR, Barnes and Yaffe,2 estimated that 2% of AD cases (about 
825,000) are attributable to diabetes and could be preventable.2 A meta-analysis of eight cohort 
studies reported up to 39% increased risk of AD associated with diabetes, and in other instances, 
mid-life diabetes was shown to be involved in the higher risk of AD at later stages in life, 
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indicating a role of longer disease duration towards the later manifestation of outcome.9 
Hyperinsulinemia is a common symptom associated with type 2 diabetes and, in this situation, 
the peripheral insulin is thought to have the potential of inflicting direct injury to the brain.4 
Peripheral insulin could bypass the blood brain barrier to the central nervous system, eventually 
attaching to the insulin receptors located in the hippocampus, the first part of the brain that is 
affected by AD.4 On the other hand, Abner et al.13 examined autopsy-verified diagnoses with 
regard to the diabetes-dementia relationship and found that although diabetes did not associate 
with higher burden of AD pathology, it was associated with significantly increased 
cerebrovascular pathology. Other clinicopathological studies have also reported no link between 
diabetes and AD14-15, but diabetes is a clear risk factor for dementia in any case. 
Based on evidence from systematic reviews and some RCTs, mid-life hypertension has been 
identified to be associated with a higher risk of AD or dementia in late life, and this has been 
consistent across several studies especially for people with blood pressure exceeding 160/95 mm 
Hg, and those with untreated cases of high blood pressure.2,9 The risk of future AD tends to be 
reduced with successful treatment of hypertension.2 Decreased risk of AD and dementia have 
been observed in participants who use antihypertensive drugs, although this was more evident in 
those who were 75 years or younger (the younger old) or those with reported long-term use of 
hypertensive medication.9 Further analysis of the effects of anti-hypertensive medications were 
carried out in clinical trials, but there was only a marginal protective effect seen among those 
who used the medications.9 On the other hand, no association was seen with late-life 
hypertension regarding AD risk.2 One of the major factors involved in the etiology of AD is 
blood-brain barrier dysfunction, to which hypertension has been shown to be a major 
contributor.4 
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Conflicting evidence has been reported on the effects of cigarette smoking on AD based on 
autopsy results.16 Smoking had been identified in early epidemiological investigations to have a 
protective effect on AD,16-17 and this has been consistent across several case control studies,18 but 
recent longitudinal studies identified it to be associated with increased risk of AD and 
dementia.2,16 Ott et al.17 however noted that the observed protective effect of smoking was 
selective to those who have APOE-4 allele indicating a possible interactive effect by this gene. 
Other evidence based on meta-analysis also indicates that current smokers have up to 80% 
significantly increased risk of AD,9 while former smokers were not associated with increased 
risk in most studies.2 AD cases attributable to smoking have been estimated to account for the 
second largest proportion of cases globally.2 This could be explained by tobacco’s inherent 
chemicals that are neurotoxic, and these largely contribute to AD risk through inflammatory and 
oxidative processes.2 
Among non-modifiable risk factors, age is regarded generally as the strongest risk factor for AD 
and dementia.1,19 The disease is observed in individuals beginning around the age of 65,1 and 
remains generally low in prevalence among those who are below 75 years with an exponential 
increase thereafter with advancing age.10,17 This association with old age could be explained in 
that certain symptoms do not manifest until several years of asymptomatic disease progression; 
for instance, amyloid (one of the hallmark proteins of AD) accumulation in the brain starts 
several years before the clinical manifestation of AD.10 
Health disparities exist with regard to race. Prevalence of AD has been observed to be more in 
African American population compared to whites.20  Another study observed the influence of 
race on AD and dementia risks to be about two-fold higher incidence among older African-
Americans and about one and half in Hispanics when compared with the older white 
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populations.1 These differences are largely explained by several other factors other than genetics, 
and some of these factors include the higher prevalence of diabetes and other cardiovascular 
diseases, lower education, and socioeconomic characteristics mainly seen among these 
populations.1 There is also a reported evidence of more instances of missed diagnoses of cases of 
Alzheimer’s disease within the African American and Hispanic populations relative to their 
white counterparts.1 
Studies have also identified an increased prevalence of dementia among populations with low 
levels of education,11 with up to 60% increased risk observed based on some meta-analysis 
results, indicating fewer years of formal education as an important risk factor in AD and 
dementia.1,9 Sando et al.21 observed a significant reduction in risk for participants who had 
between 8 and 9 years of education, and the greatest effect was seen among those with 10 to 18 
years of education compared to those who only had 6 – 7 years.11 This evidence is consistent 
with the findings documented in the “2015 Alzheimer’s Disease Facts and Figures” indicating 
that those with fewer years of education were at a higher risk of the disease when compared with 
those with higher level.1,9 Having lower education is thought to be interconnected with other 
factors that collectively predispose an individual to be at a higher risk. For instance, individuals 
with lower education are more likely to have less mentally stimulating occupations, lower social 
economic status, poorer nutrition, and are less likely to seek proper medical care.1 However, 
cognitive impairment in those with higher education or occupational attainment was observed to 
proceed more rapidly after the delayed onset.11 
APOE has a unique function of transporting cholesterol within the bloodstream.22 The gene has 
three alleles: ε2 (e2), ε3 (e3) or ε4 (e4), and every individual inherits one allele from each 
parent1,19,22. APOE-4 is a strong genetic risk factor for AD.7,11 The e4 allele is associated with an 
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increased risk of Alzheimer’s disease when compared with the e3, while e2, which is rare, is 
observed to have a protective effect.1,7 The e4 allele exerts up to 3-fold higher risk of the disease 
in individuals with one copy of the allele and 8- to 12-fold higher risk in those with two copies, 
compared to those having no e4 alleles.1,11 Evidence shows that APOE-4 accounts for about 40 to 
65 percent of individuals diagnosed with Alzheimer’s disease.1 Thus, APOE-4 is neither a 
necessary nor sufficient risk factor for AD because the disease still develops in the absence of it 
and some carriers do not get the disease.22 Individuals with APOE ε4 genotype acting in synergy 
with other vascular risk factors were observed according to Rönnemaa et al.10 to have the highest 
risk of dementia. In addition, the e4 allele gene has also shown the tendency of inflicting up to 5 
– 15 years earlier onset of AD among the carriers.7 
Finally, there is higher prevalence of AD observed in women compared to men,23,24 and women 
account for up to two-thirds of the total proportion of persons with Alzheimer’s disease in 
America according to recent findings.1 Women who had one or more children were observed to 
be at a significantly higher risk and earlier onset of AD compared to those who had none,23 
although a similar study observed no association based on this factor.25  Since women have been 
observed to live longer than men,19 this has offered some explanations regarding the higher 
prevalence of the disease in women as old age is an established risk factor for the disease.1 
Reports from incidence studies have been inconsistent regarding dementia in men and women 
with some studies observing higher incidence in women mostly only after the age of 85.24  
Ruitienberg et al.24 observed similar overall dementia incidence for men and women with a null 
value, but essentially higher incidence in women occurs after the age of 90. The women however 
showed a lower risk of vascular dementia than men in all ages. Other available evidences also 
suggest that there are far more pronounced associations of APOE-4 with AD in women when 
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compared to men,7 which might be explained by the established interaction between the APOE-4 
genotype and estrogen, the female sex hormone.1 Women with homozygous alleles of APOE-4 
gene have been observed to have around 12-fold increased risk of the disease compared with 
about 10-fold risk in men, demonstrating an evidence of gender interaction.7  
 
Birth Cohort Effects in Long-term Longitudinal Studies: 
A cohort could be defined as a group or subgroup of a population bound by a common specific 
events, like a particular life exposure or non-specific exposure.26 People who were born in the 
same year or period of time are referred to as birth cohort,26 and study participants belonging to 
the same birth cohort may be exposed to similar environmental, societal life events or risk factors 
different from those belonging to a different birth cohort, thereby resulting in differences in 
health outcomes several decades later.26-27 For example, risks associated with age may be 
different in different birth cohorts. Cohort effects therefore occur if membership in a particular 
cohort influences the development of the disease outcome.26,28 It could also be defined as 
differences in the occurrence of a health outcome according to a defined cohort with respect to 
their exposure to certain risk factors over time.29 To analyze a birth cohort, the morbidity or 
mortality rate of the cohort, grouped by age is observed longitudinally as they move through 
time.26,29 Risk factors or exposures could be examined in a similar fashion, to understand past 
population health trends, and possibly assist in predicting future health outcomes.30 There are 
often variations in secular trends regarding environmental exposures or risk factors across 
different stages in life, and these have led to the conceptualization of cohort effect as an 
interaction of both period and age effects.30 Cohort effects could be identified when there is an 
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upward or downward trend in risk of the disease or when there is a change of direction of 
effect.27 
The birth cohorts in this study were constructed around the following historical periods: World 
War I (WWI, 1914-1918), the Roaring 20s (1919-1928), Great Depression (1929-1938), World 
War II (WWII, 1939-1945), and the Baby Boom (1946-1964). These represent important, well 
defined periods in US history, within which exposures to major environmental and societal 
events occurred. For example, in addition to the WWI, the flu pandemic of 1918 occurred during 
1914-1918. In the United States, WWII led to about 405,000 deaths among service men and 
women and 671,000 injuries.31 
Keinan-Boker et al.32 examined the theory of Fetal Origin of Adult Disease (FOAD), which 
focused on the impacts of war related prenatal/early life exposures including famine or hunger 
and how they influence future risks of certain health outcomes through a mechanism referred to 
as fetal programming.32 According to the study, being born during the time of war, often with 
observable fetal experiences like low birth weight, was identified as an independent predictor of 
hypertension, diabetes mellitus, vascular diseases, metabolic syndromes, mental health issues 
and cognitive functions with the observed odds ratios showing strong associations with the 
diseases.32  A pregnant mother during the time of war is likely to experience poor nutrition, often 
leading to low birth weight, which has been shown to be linked with hypertension because of a 
reduced functional capacities of essential organs in the body like the kidneys.33-34 Prenatal or 
early life malnutrition may also induce some changes in certain hormones and metabolic 
pathways which may influence the individuals susceptibility to long term chronic conditions.32,34  
Economic downturns have also been observed to have some impacts on the health of the 
population, and one such important economic event that occurred in the US is the Great 
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Depression of the 1930’s, which started in mid-1929 and lasted officially until 1933, although 
the effects remained through about 1938, towards the beginning of World War II.35 In economic 
terms, depression is a period marked by severe declines in economic activities with a marked 
higher level of unemployment.35 Changes in health indicators and economic activities have been 
compared using correlation and regression models, and it was observed that the health indicators 
of the population generally improved during the period of the Great Depression between 1930 
and 1933 for all races. There was a gain in life expectancy and a decrease in both infant and 
overall mortality rates for all causes except for those due to suicide which increased within this 
period with a contribution of about 2% to the total number of deaths.35 The potential effects of 
stress as a result of Great Depression in utero was studied in participants later in life, and there 
was no association seen relating the exposure to chronic diseases.36 Conversely, mortality rates 
were shown to peak during the periods of economic expansion seen between 1923 and 1929.35 A 
possible explanation of poor health outcomes during the periods of economic expansion is linked 
with increases in smoking and alcohol consumption, reduction in sleep, increases in work load 
and associated stress, and increases in economic activities and atmospheric pollution.35  
The Baby Boomers represent the generation of people born between 1946 and 1964 and make up 
to 26.1% of the overall US population.37 Available information indicates important differences 
between them and the preceding generation.38 For example, the Baby Boom generation is 
expected to have longer life expectancies compared to previous generations due to several 
advancements in medicine. But, despite these factors, this generation have been observed to be 
more likely to have chronic health conditions including diabetes, hypertension, obesity and other 
disabilities.37 They are also more likely to have higher income, lower rates of marriage, and 
fewer children compared to the previous generation.38 Smoking prevalence among this 
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generation was on the other hand, observed to be less when compared with the previous 
generation.37  The proportion of US population with AD is estimated to increase in the coming 
years as the baby boom generation progressively attain the age of risk.1 There is a greater 
likelihood of increased cost and burden on the healthcare as a result of the influence of this 
generation as they age due to their large numbers.3,37 
The idea of considering secular life events in the categorization of the birth cohorts is to access 
the holistic effects of individuals’ full lifetime exposures on the manifestation of disease 
outcomes, and this is based on the concepts of life course epidemiology.27 Since the birth cohorts 
were grouped historically based on critical environmental conditions, it is expected that these 
exposures may have effects on those individuals later in life. A similar study of birth cohorts 
regarding abdominal obesity have been carried out by Robinson et al.30 in which they grouped 
the cohort as Silent Generation, Great Depression, Baby Boomers or Generation X. 
 
A Life Course Approach to Future Health Outcomes: 
Life course epidemiology is the study of the effects of long-term physical, social or behavioral 
exposures at earlier stages in life (including gestation, childhood, adolescence, early and matured 
adulthood) towards the later manifestations of health outcomes or disease risks.27,39 Generally, 
health conditions are expected to deteriorate as people age,40 however, the development of 
chronic disease in adulthood may be related to the effects of environmental exposures like 
malnutrition during periods of war, economic depression, etc., on critical developmental stages 
in utero.27 Life course epidemiology, however, also explains how behavioral risk factors such as 
smoking, alcohol consumption, diet and exercise influence the onset and progression of disease 
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in adulthood, and also provides further explanations on gender, ethnic and geographical 
differences in disease trends.27 
 
MATERIALS AND METHODS: 
Sample and Data Source: 
The sample consists of 10,250 cognitively intact normal control individuals without any form of 
dementia and 12,702 cases with clinically diagnosed AD (including MCI and dementia). Cases 
and controls were derived from the Uniform Data Set (UDS) of the National Alzheimer’s 
Coordinating Center (NACC). These de-identified data are from the December 1, 2014 UDS data 
freeze. There are 29 designated Alzheimer’s Disease Centers (ADCs) funded by the National 
Institute on Aging (NIA) of the National Institutes of Health (Bethesda, MD).41 The NACC 
database is built from a longitudinal studies of aging with participants enrolled at ADCs as either 
normal, those with mild memory problems, or those diagnosed with dementia.42 The follow up of 
participants involves annual longitudinal data collection with neurological exams, cognitive 
testing and functional assessments done at each visit through interviewer-administered 
questionnaires.42 An Institutional Review Board (IRB) at each ADC approved all research 
activities, including data sharing. All participants provided written informed consent. This 
secondary analysis of the de-identified data did not require IRB approval. 
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Inclusion / Exclusion Criteria: 
The inclusion/exclusion criteria for the selection of cases and controls is based on the presence or 
absence of the disease outcome at the initial UDS visits to the center. Standardized clinical 
assessments, medical tests, physiological and cognitive functioning examinations are obtained 
from each participant at the time of enrollment in the study and these are repeated at every yearly 
follow up visit.43 
The current dataset was limited to individuals whose dates of birth were between 1896 and 1955 
in other to be sure of including only those considered to be at risk based on their age. The study 
sample also was limited only to the participants’ initial visit in other to avoid multiple entries 
from the same individual and to help avoid effects of therapeutic studies the participants may 
have engaged in after enrollment at their ADC. Of the 77,389 observations included in our initial 
dataset, 55,515 were excluded because they represented follow-up visits, and 992 were removed 
because they were not considered to be at risk based on their age. The final analytic sample was 
made up of 22,952 individuals (Figure 1). 
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Figure 1. Participant inclusion flow chart. Participants were derived from the National 
Alzheimer’s Coordinating Center’s Uniform Data Set (December 2014 freeze). 
 
Birth Cohorts: 
The study sample was sub-divided into five birth cohorts based on historical periods described 
above. Specifically, cohorts were constructed for the period leading up and through the end of 
WWI (Birth Cohort 1; born 1896-1918), Post WWI/the Roaring 20s (Birth Cohort 2; born 1919-
1928), Great Depression/Pre WWII (Birth Cohort 3; born 1929-1940), WWII (Birth Cohort 4; 
born 1941-1945), and Baby Boom Cohort (Birth Cohort 5; born 1946-1955). Odds ratios for 
each risk factor of interest were estimated using logistic regression analysis within each cohort in 
order to assess potential effect measure modification by birth cohort. 
Total of 77,389 observations included 
in the original data set 
 
23,874 observations retained based on 
the participant’s initial visit to the 
center 
Observations excluded because they 
represented follow-up visits from the 
same participant (n = 53,515) 
Excluded 
Observations excluded because they 
represented participants who were 
born beyond the year 1955 
 (n = 992) Excluded 
22,952 participants included in the 
final study population for Birth Cohort 
effect. 
10,250 observations 
included in the study 
as Controls 
 
12,702 observations 
included in the study 
as the Cases 
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Independent Variables: 
Participant age (years), sex (male = 1, female = 2), and years of education were determined 
based on UDS demographic data. Participant race was coded as in the UDS as White, 
Black/African American, American Indian/Alaskan native, Native Hawaiian/other Pacific 
Islander, Asian, and multiple races, but was grouped into three categories for analysis: White (= 
1), Black (= 2), and Other (=3). Insufficient numbers of Other race in Birth Cohort 1 did not 
allow for all three categories, and White vs. Non-White was used instead for this cohort. Health 
conditions including diabetes and hypertension are assessed in the UDS by clinician interview 
with the participant or their study partner (i.e., someone who knows the participant well and can 
provide data for cognitively impaired participants). Diabetes status (1=history of diabetes, 0=no 
history of diabetes) was captured based on self-report at the time of visit and was not 
differentiated between Type I and II. We assumed that it represented Type II diabetes based on 
the available evidence that Type I diabetes is rare in individuals over the age of 60.13 
Hypertension was coded similarly (1=history of hypertension, 0=no history of hypertension). 
Smoking exposure was classified as active smokers (=1), which were those who were actively 
smoking in the last 30 days, and non-smokers (=0) were those who did not smoke in the last 30 
days. In order to ascertain the total lifetime exposure to smoking, smoking pack-years was 
estimated by the multiplying the reported duration of smoking in years by the average number of 
packs of cigarettes smoked in a day. The APOE genotype was recoded for analyses by 
categorizing the participants without any e4 alleles as 0 while those with either one or two e4 
alleles were classified as 1. Number of biological children was collected on the UDS family 
history interview. 
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Cognitive Assessments: 
The UDS neuropsychological evaluation is based on a standardized test battery by trained 
interviewers. The neuropsychological test battery is made up of several cognitive domains (e.g., 
memory, processing speed, executive function, language). Instruments include the Mini-Mental 
State Examination (for testing cognition),44 the Boston Naming Test, Animal Naming Test, 
Vegetable Naming Test, Wechsler Logical Memory, Trail Making Test A and B, Digit Span 
Forward and Backward, and Digit-Symbol Substitution.45 
 
Case Ascertainment: 
Participants’ cognitive status is classified at each UDS visit.41 Diagnoses are based on the 
consensus opinion of the examining neurologist and other clinicians and research assistants who 
examined the participants. Participants who are classified as normal performed within 
expectation on the neuropsychological tests and are functionally intact. Participants who are 
determined to be not normal are further classified as having MCI or dementia, and both MCI and 
dementia are furthered classified by suspected etiology. Dementia is classified according the 
criteria of the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) and the 
diagnosis of AD is based on internationally acceptable criteria.46 
 
Statistical Analyses: 
We carried out descriptive statistical analyses of all risk factors of interest to compare 
distributions with respect to these risk factors among the cases and the controls, as well as the 
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distributions among the five birth cohorts as categorized. Means and standard deviations were 
calculated for the continuous variables, while frequencies and percentages were computed for 
categorical variables. Age, level of education, number of kids, and tobacco smoking exposure (in 
pack years) were included as continuous variables, while the categorical variables included 
gender, race, hypertension, diabetes medication, antihypertensive medication, active smoking 
status, and APOE. 
Case-control study design was employed, where the cases represent those diagnosed with AD, 
and controls are those who were ascertained to have normal cognition as at the time of initial 
visit. All analyses were performed to determine the crude estimate as well as after adjustment for 
the other factors included in the model. The effects of the individual risk factors were first 
estimated by including them separately in univariate logistic regression models. Multivariable 
logistic regression analysis was used to estimate the adjusted odds ratios (OR) and 95% 
confidence intervals (CI) for the observed association between AD and the risk factors, 
excluding APOE due to significant missingness (29.6%). A logistic model was constructed for 
the overall sample in addition to five models for the birth cohorts. For the categorical variables 
diabetes, hypertension, APOE-4, and smoking status, we computed the OR using the absent level 
as the reference category. For race, we used the “White” category as the reference, while the 
females served as the reference for the gender. A sensitivity analysis was carried out including 
APOE in the model. Secondary analyses were performed restricted to the female participants to 
assess the association between their number of children and AD, and again with a sensitivity 
analysis for the additional effect of APOE. Statistical significance for our logistic models was set 
at 0.05, and all analyses were performed using SAS statistical software version 9.4 (SAS 
Institute, Inc., Cary, NC). 
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RESULTS 
Descriptive data 
A total of 22,952 subjects, 12,702 with AD and 10,250 normal controls were included in the 
study. The descriptive statistics of the samples are shown in Table 1. The final analytic sample 
was made up of 40.25% men (n=9,239) and 59.75% women (n=13,713). The racial composition 
of the sample was 80.71% White (n=18,469), 14.58% Black/African American (n=3,337), and 
4.70% Other (n=1,076).  
The participants were categorized into 5 birth cohorts based on their years of birth: 5.27% of the 
participants (n=1209) were categorized as Pre WWI till the end of WWI (Birth Cohort 1), 
30.25% of the participants (n=6943) were categorized in the Post WWI and Roaring 20s cohort 
(Birth cohort 2), 38.16% of the participants (n=8,759) were categorized in the Great Depression 
to the start of WWII Cohort (Birth Cohort 3), 13.07% of the participants (n=2,999) were 
categorized in the World War II Cohort  (Birth Cohort 4), and 13.25% of the participants 
(n=3,042) were categorized in the Baby Boom Cohort  (Birth Cohort 5). Table 2 shows the 
descriptive characteristics for the five birth cohorts. The percentages for all the categorical 
variables were shown to be fairly evenly distributed across the groups. The Baby Boom (Birth 
Cohort 5) was younger at baseline than the other cohorts, and was in addition to WWII (Birth 
Cohort 4) observed to have the highest level of education with over 15 years or more mean 
education years compared to other birth cohorts. The gender distribution across all the birth 
cohorts showed that the females accounted for the majority of participants in all birth cohorts at 
approximately or exceeding 60%, and nearly all the birth cohorts had 80% of the participants as 
White. Active smoking status was shown to increase across time and was seen to be highest in 
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the Baby Boom Cohort with about 6.24% of participants observed to have been actively smoking 
in the past 30 days.  The earlier born cohorts (1 to 3) were observed to have about 50% of 
participants smoking 15 pack-years of cigarette or more compared to the later born birth cohorts 
that smoked approximately 12 pack-years or less. The Baby Boom cohort (Birth Cohort 5) 
reported the least hypertension, followed by Birth Cohort 4, compared to the preceding cohorts. 
Diabetes status did not differ markedly across all groups. Likewise, APOE-4 status was 
relatively consistent, though the WWI birth cohort (Birth Cohort 1) had the lowest APOE-4 
prevalence. For the women, the Birth Cohort 5 were shown to have the lowest number of 
children, with mean value of less than two compared to other birth cohorts. 
 
Univariate analysis 
In the whole sample, all the risk factors except for active smoking were significantly associated 
with AD. The univariate logistic regression analysis shows an association between age, 
education, lifetime smoking exposure in pack-years, active smoking status, sex, race, APOE-4, 
hypertension, and diabetes with AD. The risk factors were associated with dementia in the model 
at p<0.05 (Table 3). The effect of a 1-year increase in age was observed to increase the odds of 
AD between 1% to 8% across birth cohorts [(OR: 1.01, 95% CI: 0.98 – 1.03), to (OR: 1.08, 95% 
CI: 1.07 – 1.09)] in Birth Cohorts 4 and 3 respectively, and a 4% decrease in odds was seen in 
the Baby Boom cohort with the estimated OR = 0.96 (95% CI: 0.95 – 0.98). A 1-year increase in 
education had a protective effect of about 8% - 12% decrease in odds across all birth cohorts, 
with an estimated OR = 0.92 (95% CI: 0.90 – 0.94) in Birth Cohort 4 and OR = 0.88 (95% CI: 
0.86 – 0.91) observed in Birth Cohort 5. Active smoking status was observed to be associated 
with an estimated 30% (Birth Cohort 4) and 18% (Birth Cohort 5) non-significant increase in the 
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odds of AD. Males had higher odds of AD (17% - 66%), which was significant in all but Birth 
Cohort 2. Hypertension and diabetes exhibited only a marginal relationship with AD, although a 
stronger association was observed with diabetes. Those who used diabetes medication showed 
almost 30% increased risk of having AD in the earlier born cohorts (1, 2, and 3) compared to the 
later ones, where protective effects were seen. Medication use was not included in the final 
multivariate models as it did not change the overall effect estimates as most participants with 
these conditions were medicated, and we were concerned about collinearity. 
 
Multivariable analyses 
We obtained adjusted ORs for all the variables by including them together in a multivariable 
model (Table 4). In the total sample, effect measures were attenuated in the multivariable model, 
except for male sex, where there was at least a 36% increase. Among the risk factors included, 
age, education, sex and race were the only variables shown to retain their significance. 
The effects of age remained consistent across all the birth cohorts, although a weak reversal of 
effect was seen in Birth Cohort 1 (OR: 0.99, 95% CI: 0.91 – 1.07). Estimates for education 
remained relatively stable, with about 11% reduced odds seen for every one-year increase in 
education. There was a significantly increased odds observed regarding gender, and males were 
seen to have significantly higher odds of AD in all birth cohorts. The effect of hypertension was 
inconsistent in Birth Cohort 3, with a non-significant reduction in odds (OR: 0.92, 95% CI: 0.80 
– 1.06). The total lifetime smoking exposure was estimated in pack-years, and there were 
marginal effects of about 1 – 3% higher odds seen between Birth Cohorts 1 to 4, and a protective 
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effect of about 3% seen in the baby boom cohort for every 10 pack-years increase in cigarette 
smoked.  
Further adjusted estimates in the multivariate model were obtained by adding APOE to the 
model, and it was observed to exert substantial increase in the effect estimates with over 3-fold 
higher risk seen in the birth cohorts 1 – 4. Participants missing APOE were excluded from this 
analysis. 
 
Relationship between women and AD 
When the sample was regrouped based on sex and a separate analysis was performed on women 
alone, interesting patterns emerged. Table 6 shows the adjusted odds ratios for the women with 
respect to the already established risk factors. Age and number of children were observed to be 
associated with increase in odds of AD in all the birth cohorts, except for Birth Cohort 5 and 4 
respectively. Education was consistent with the previous model (Table 5), and having higher 
education was associated with a reduced odds of AD in all birth cohorts. 
Active smoking and hypertension were mostly shown to be more associated with the outcome in 
the later birth cohorts (4 and 5) compared to the those born earlier, and those who use diabetes 
medication were observed to have reduced risk in all birth cohorts (not shown). Having an 
additional one child increased odds of AD across all cohorts, except in Birth Cohort 4, and the 
greatest effect of about 10% higher risk was seen in birth cohorts 1 and 3, where the effect was 
significant. 
The effect of APOE in women was also examined (Table 7), and there was little change in effect 
estimates with this additional factor. The adjusted OR for APOE was observed to be stronger in 
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all the birth cohorts when restricted to just women (Table 7) compared to the to the model that 
also included males (Table 5). The effects of other risk factors remained almost the same for age, 
education, kids and smoking, but a reversal was seen for hypertension in Birth Cohorts 3 and 5, 
which showed protective effects. 
 
DISCUSSION 
We explored the presence of birth cohort effects in AD in the United States using data from the 
National Alzheimer’s Coordinating Center with our included participants born between 1896 to 
1955.  A discussion of our key findings appears below. 
Associations between established risk factors and AD 
Higher odds of AD was observed in men compared to women in our study. Possible explanations 
regarding this trend could be based on the fact that there are often less symptomatic outcomes in 
women regarding cerebrovascular pathologies, or as a result of survival bias between men and 
women regarding this data in a situation where men selectively survive more than women.24 
There was no evidence suggesting the presence of interaction based on age or smoking as they 
were equally investigated (results not shown). 
Our findings on smoking provide some support to the already existing evidence based on 
epidemiologic studies on the negative effects of smoking on AD. Smoking exposure, as 
measured by pack-years in the main multivariate model (Table 4), was however seen to be non-
significantly associated with the disease as observed in our birth cohorts (1 - 4), and even though 
an elevated odds was observed, the effect was not as strong as earlier findings,17 which showed a 
risk of 2.5 higher for those with less than 20 pack-years of exposure and 3.0 higher risk of 
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dementia for those with more than 20 pack-years of exposure.17  For the Baby Boom cohort, 
which was observed to be less likely to be smokers with about 75% of them smoking about 25 
pack-years of tobacco or less, which is consistent with earlier findings that smoking prevalence 
among this generation was observed to be less when compared with the previous generation,37  
there was a protective effect with respect to AD compared to the preceding birth cohorts, in 
which 75% of the participants smoked a minimum of 30 pack-years of cigarettes, and were all 
shown to have increased odds (although marginal). Additionally, studies that seem to support the 
protective effects of smoking towards the AD were observed not to have accounted for total 
lifetime smoking exposure.16 Variations in risk of dementia related to smoking and hypertension 
have been observed as participants age.10 There could be survival bias in terms of the fact that 
some participants may have developed dementia and died prior to be recruited for studies and are 
thereby not accounted for in the overall risk estimate in this group.10 Active smoking exposure 
was shown to be non-significantly associated with increased odds of AD, and this was consistent 
with findings from several studies that did not support the hypothetical neuroprotective effect of 
smoking towards AD development.16 The effects of the active smoking status towards the 
development of AD should be interpreted with caution because, evidence from other case control 
study designs indicated smoking to have a protective effect which was not consistent with 
prospective studies.17,18 This could be due to survival bias where smokers with AD die faster 
than nonsmokers with AD prior to inclusion in case-control studies.18 
Hypertension was not significantly associated with odds of AD in our adjusted analyses. Effect 
estimates observed with respect to hypertension were higher in the later cohorts (4 and 5), with 
about 12% and 4% elevated odds respectively. Since it has been observed that there is a 
decreased risk of AD and dementia in participants who use antihypertensive drugs, more 
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evidently observed among those who were 75 years or younger (the younger old) or those with 
reported long-term use of hypertensive medication,9 this could offer some explanations. 
However, without detailed medication data, we could not explore these relationships. We also 
did not have data on mid-life hypertension. 
The protective effect of education on odds of dementia was observed to be highest in the baby 
boom cohort (estimated OR: 0.88, 95% CI: 0.84 – 0.92), and an explanation to this may be that 
this group was more highly educated on average.8 Birth Cohort 5, as well as the Cohort 4, had the 
highest years of education with the mean exceeding 15 years compared to the preceding cohorts, 
which were all less than 15 years on average. Dose-dependent protective effect of education 
towards AD has been studied in all age groups in both men and women,21 and the results from 
our study seem to be in agreement with this finding. Birth Cohort 1, which had the lowest mean 
years of education 13.80 ± 3.94 (Table 2), yielded the weakest protective effect (OR: 0.93, 95% 
CI: 0.87 – 0.99) in the multivariate model (Table 4). Birth Cohort 5, which had the highest mean 
of years of education (15.59 ± 3.06), showed a stronger protective effect of education (OR: 0.88, 
95% CI: 0.84 – 0.92), although the two estimates are not significantly different.  
The results from our study emphasize the importance of age on the development of AD. Age has 
been observed as the strongest risk factor for AD and dementia, often beginning around the age 
of 65 with a low prevalence in individuals below the age of 75.1 There was about 3% negative 
effect of age toward AD in Birth Cohort 5 (estimated OR: 0.97, 95% CI: 0.93 – 1.02) in the 
multivariate model (Table 4), but since the mean age of this group is about 59.91 ± 3.69, this 
tends to support the fact that after there is less risk of the disease in this age group.10 There were 
elevated risks of AD seen in Birth Cohorts 2, 3 and 4 for every one-year increase in age. Over 
two-fold elevated risk of AD based on race was seen in Birth Cohort 2 with the estimated 
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adjusted OR: 2.18 (95% CI: 1.42 – 3.34) (Table 4), and in all instances, other races were seen to 
have much higher odds of the disease compared with whites which supports the fact that the 
influence of race on AD and dementia risks is about two-fold higher incidence among older 
African-Americans and about one and half in Hispanics when compared with the older white 
populations.1  
The effect of APOE was also explored and was seen to exert over three-fold higher odds of AD 
and dementia in all the birth cohorts, except Birth Cohort 5, where it had over two-fold higher 
risk. The associations between APOE and AD should however be interpreted with caution based 
on this data because of the large proportion of missing values (29.6%). APOE has earlier been 
identified as an effect modifier as it conferred a higher risk of dementia to smokers without 
APOE-4 allele.17  
 
Cohort Effects in Alzheimer’s disease  
Cohort effects are present if membership in a particular cohort of participants in a study 
influences the development of the disease outcome.26 A cohort effect is expected to occur in 
longitudinal studies if a population level environmental exposures or certain risk factors are not 
evenly distributed among the participants in the study. Cohort effects could be identified when 
there is an upward or downward trend in risk of the disease or when there is a change of 
direction of effect.27 These data suggest that there may be many contributory factors to 
individuals’ risk of AD and dementia based on the particular time they were born, and there is an 
evidence of change in risk over time as seen from the results of the analyses. 
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There was evidence of variation in the point estimates for cohort-specific risk factors (age, active 
smoking, gender, race, hypertension and diabetes) when compared with the overall estimate. A 
strong positive cohort effect was observed in Birth Cohort 1 (for the period leading up and 
through the end of WWI 1896-1918), Birth Cohort 3 (Great Depression/Pre WWII 1929-1940), 
Birth Cohort 4 (the WWII born 1941-1945), and Birth Cohort 5 (Baby Boom Cohort born 1946-
1955). Stepwise comparisons were made with the overall crude estimates of the odds ratios, and 
there were at least 5% change in effect estimates with respect to the risk factors. There was a 
negative cohort effect observed in the Birth Cohort 5 with respect to age, and this could lead to 
an assumption that the participants represented in this group were less susceptible to the effects 
of age to the development of the disease. Diabetes exerted over 12% change in effect in Birth 
Cohorts 2, 3 and 4, a trend similar to what was observed with the hypertension variable. The 
cohort marked by the period of Great Depression showed better attenuated effects with respect to 
smoking and hypertension, which was observed to have a reduced estimate. This is consistent 
with earlier findings that health indicators of the population generally improved during the 
period of the Great Depression between 1930 and 1933 for all races with a gain in life 
expectancy and a decrease in both infant and overall mortality rates for all causes.35 
In summary, the individual effects of the examined risk factors regarding AD and dementia were 
similar to existing information based on previous literature, but effect estimates varied within 
cohorts. Even though there was a reverse trend seen based on gender and this may likely be a 
possible area of further investigation regarding this data set and the data collection procedures. 
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STRENGTHS AND LIMITATIONS: 
An important strength of this study is that it compared comparatively large sub-cohorts of the 
same population, and there were identical assessments of both the risk factors and the outcome 
(AD). Participant cognition was carefully assessed and involved detailed clinical and 
neuropsychological evaluations by trained professionals. However, NACC is not a population-
based sample since most ADC participants are required to consent to autopsy in order to enroll. 
People who are willing to donate their brains to science are different than the general population 
of older adults. They tend to be highly educated, with high socioeconomic status. There is also 
the tendency that NACC does not reflect the general population because participants selectively 
agree to participate only at academic medical centers, and the ADCs also do not recruit those 
with severe dementia as would be found in a community setting.41  
Potential biases in the study include the possibility of misclassification of AD cases during the 
data collection process, because of the coexistence of AD with other brain diseases. Participants 
with a different brain disease might be diagnosed with AD, which complicates the diagnosis path 
both clinically and pathologically.17 However, we would expect this misclassification to be non-
differential with respect to the risk factors of interest.  Moreover, some controls could be 
asymptomatic cases. We did not have detailed information on severity and duration of 
comorbidities or medication use, and there could be residual confounding due to inadequate 
measurement of the covariates. Birth cohorts were based on historical events, but could have 
been constructed differently. This may have influenced our results. Lastly, we only considered 
the baseline data. Results may have changed if we focused on later data.  
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PUBLIC HEALTH IMPLICATIONS: 
Evaluation of risk factors to be targeted for prevention depends on careful estimation of effect 
estimates. We provided evidence that effects of risk factors may vary depending on birth cohort. 
Knowledge of cohort effects is very useful in predicting future trends of AD and dementia,30 
especially with the current aging of the global population and the predicted catastrophic increase 
in the burden of dementia. 
 
CONCLUSION:  
In conclusion, we showed that age, gender, education, active cigarette smoking as well as 
lifetime smoking, race, hypertension and diabetes influenced the odds of AD. Furthermore, 
evidence of cohort effects was observed in our study as the estimates and significance of risk 
factors differed among the cohorts. Despite the limitations of this study, information was 
provided on important risk factors associated with AD, and their effects in birth cohorts with 
emphasis on historical events. More research is required to provide a better understanding of the 
association between these risk factors and AD, especially with respect to the sample inclusion 
criteria and the observation of a possible selection bias. 
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Table 1: Comparison of Characteristics among persons with and without Dementia 
 
Variables 
 
All Participants  
(n 22,952) 
 
Cases (Dementia) 
(n = 12702) 
 
Controls/Normal 
Cognition (n = 10250) 
Age (n) 22952 12702 10250 
Mean ± SD 74.13±9.06 75.49±8.89 72.45 ±8.98 
    
Education (n) 22834 12631 10203 
Mean ± SD 14.89±3.57 14.31±3.84 15.61±3.07 
    
Pack-years of smoking (n) 9518 5041 4477 
Mean ± SD 22.64 ± 23.70 23.99±24.57 21.11±22.59 
    
Active Smoking    
0 – No 21910 (95.97) 12130 (96.09) 9780 (95.83) 
1 – Yes 919 (4.03) 493 (3.91) 426 (4.17) 
    
Gender    
1 – Male 9239 (40.25) 5697 (44.85) 3542 (34.56) 
2- Female 13713 (59.75) 7005 (55.15) 6708 (65.44) 
    
Race    
1 – White 18469 (80.71) 10182 (80.39) 8287 (81.11) 
2- Black/African American 3337 (14.58) 1775 (14.02) 1562 (15.29) 
3 – Others 1076 (4.70) 708 (5.59) 368 (3.60) 
    
Hypertension    
0 – No 10817 (47.30) 5802 (45.82) 5015 (49.12) 
1 – Yes 12054 (52.70) 6860 (54.18) 5194 (50.88) 
    
Antihypertensive Medication    
0 – No 10338 (45.74) 5567 (44.28) 4771 (47.57) 
1 – Yes 12264 (54.26) 7005 (55.72) 5259 (52.43) 
    
Diabetes Medication    
0 – No 20359 (90.08) 11252 (89.50) 9107 (90.80) 
1 – Yes 2243 (9.92) 1320 (10.50) 923 (9.20) 
    
Diabetes    
0 – No 19907 (87.03) 10908 (86.19) 8999 (88.08) 
1 – Yes 2966 (12.97) 1748 (13.81) 1218 (11.92) 
    
APOE Genotype    
0 – No 9213 (57.02) 4010 (45.61) 5203 (70.63) 
1 – Yes 6945 (42.98) 4781 (54.39) 2164 (29.37) 
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Table 2: Comparison of Demographic and Clinical Characteristics of the Study Sample by Birth Cohort. 
Variables All 
Participants 
(n 22,952) 
Birth Cohort 1 
1,209 (5.27 %) 
Birth Cohort 2 
6,943 (30.25 %) 
Birth Cohort 3 
8,759 (38.16 %) 
Birth Cohort 4 
2,999 (13.07 %) 
Birth Cohort 5 
3,042 (13.25 %) 
  Cases 
757 
 
Controls 
452 
Cases 
4498 
Controls 
2445 
Cases 
4795 
Controls 
3964 
Cases 
1333 
 
Controls 
1666 
Cases 
1319 
Controls 
1723 
       
Age 22952 1209 6943 8759 2999 3042 
Mean ± SD 74.13 ± 9.06 91.04 ± 3.12 82.05 ±3.38 73.24 ± 3.80 66.00 ± 2.84 59.91 ± 3.69 
       
Education 22834 1199 6905 8730 2977 3023 
Mean ± SD 14.89 ± 3.57 13.80 ± 3.94 14.40 ± 3.72 14.97 ± 3.56 15.51 ± 3.31 15.59 ± 3.06 
       
Number of Children 22267 1135 6709 8516 2924 2983 
Mean ± SD 2.56 ± 1.85 2.49 ± 1.99 2.91 ± 2.05 2.72 ± 1.85 2.06 ± 1.47 1.82 ± 1.31 
       
Pack-years of smoking        
25th pctile  5.00 5.50 5.00 5.00 4.25 3.75 
50th pctile  15.00 15.00 15.75 15.00 12.50 10.50 
75th pctile   33.75 31.25 37.50 35.00 30.00 25.00 
100th pctile  198.00 121.50 198.00 198.00 198.00 198.00 
       
Active smoking       
0 – No (n %) 21910 (95.97) 1178 (98.33) 6702 (97.17) 8381 (96.13) 2810 (94.04) 2839 (93.76) 
1 – Yes (n %) 919 (4.03) 20 (1.67) 195 (2.83) 337 (3.87) 178 (5.96) 189 (6.24) 
       
Gender       
1 – Male (n %) 9239 (40.25) 436 (36.06) 2979 (42.91) 3580 (40.87) 1134 (37.81) 1110 (36.49) 
2- Female (n %) 13713 (59.75) 773 (63.94) 3964 (57.09) 5179 (59.13) 1865 (62.19) 1932 (63.51) 
       
Race       
1 – White n, (%) 18469 (80.71) 1044 (86.50) 5665 (81.73) 6974 (79.89) 2396 (80.11) 2390 (79.03) 
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2-Black / African 
American n, (%) 
3337 (14.58) 128 (10.60) 947 (13.66) 1359 (15.57) 446 (14.91) 457 (15.11) 
3 – Others (n %) 1076 (4.70) 35 (2.90) 319 (4.60) 396 (4.54) 149 (4.98) 177 (5.85) 
       
Hypertension       
0 – No (n %) 10817 (47.30) 484 (40.27) 2771 (40.07) 4014 (45.96) 1637 (54.73) 1911 (63.07) 
1 – Yes (n %) 12054 (52.70) 718 (59.73) 4144 (59.93) 4719 (54.04) 1354 (45.27) 1119 (36.93) 
       
Diabetes       
0 – No (n %) 19907 (87.03) 1097 (90.81) 6070 (87.72) 7434 (85.16) 2613 (87.63) 2693 (88.76) 
1 – Yes (n %) 2966 (12.97) 111 (9.19) 850 (12.28) 1295 (14.84) 369 (12.37) 341 (11.24) 
       
APOE Genotype       
0 – No (n %) 9213 (40.14) 678 (56.08) 2947 (42.45) 3276 (37.40) 1189 (39.65) 1123 (36.92) 
1 – Yes (n %) 6945 (30.26) 238 (19.69) 1866 (26.88) 2911 (33.23) 995 (33.18) 935 (30.74) 
Missing (n %) 6794 (29.60) 293 (24.23) 2130 (30.68) 2572 (29.36) 815 (27.18) 984 (32.35) 
 
Birth Cohort 1 (born 1896-1918) = The period leading up and through the end of WWI, Birth Cohort 2 (born 1919-1928) = Post WWI/the Roaring 20s, Birth Cohort 3 (born 
1929-1940) = Great Depression/Pre WWII, Birth Cohort 4 (born 1941-1945) = WWII, Birth Cohort 5 (born 1946-1955) = Baby Boom Cohort 
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Table 3: Univariate Logistic Regression Analysis of Individual Risk factors for Cognitive Impairment and Alzheimer’s Disease. 
 
 
Variables 
All Participants 
(n 22,952) 
Birth Cohort 1 
1,209 (5.27 %) 
Birth Cohort 2 
6,943 (30.25 %) 
Birth Cohort 3 
8,759 (38.16 %) 
 
Birth Cohort 4 
2,999 (13.07 %) 
Birth Cohort 5 
3,042 (13.25 %) 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
      
Age 1.04 (1.04-1.04) ** 1.03 (0.99-1.07) 1.03 (1.02-1.05) ** 1.08 (1.07-1.09) ** 1.01 (0.98-1.03) 0.96 (0.95-0.98) * 
       
Education 0.90 (0.89-0.90) ** 0.90 (0.87-0.93) ** 0.90 (0.89-0.92) ** 0.91 (0.90-0.92) ** 0.92 (0.90-0.94) ** 0.88 (0.86-0.91) ** 
       
Pack-years of smoking 1.05 (1.04-1.07) ** 1.06 (0.97-1.16) 1.04 (1.01-1.07) * 1.04 (1.01-1.07) * 1.06 (1.01-1.11) * 1.03 (0.97-1.10) 
       
Active smoking (Y vs N) 0.93 (0.82-1.07) 0.72 (0.30-1.76) 1.00 (0.74-1.34) 0.91 (0.73-1.13) 1.30 (0.96-1.76) 1.18 (0.88-1.58) 
       
Gender (M vs F) 1.54 (1.46-1.63) ** 1.17 (0.91-1.49) 1.32 (1.19-1.46) ** 1.66 (1.52-1.81) ** 1.60 (1.38-1.86) ** 1.65 (1.42-1.91) ** 
       
Race       
African American vs Whites 0.93 (0.86-1.00) * 2.18 (1.42-3.34) * 1.13 (0.98-1.31) 0.90 (0.80-1.01) 0.79 (0.65-0.98) * 0.71 (0.58-0.88) * 
Others vs Whites 1.57 (1.38-1.78) ** 7.12 (2.17-23.41) * 1.99 (1.52-2.60) ** 1.72 (1.39-2.13) ** 1.20 (0.86-1.67) 1.22 (0.90-1.66) 
       
Hypertension (Y vs N) 1.14 (1.08-1.20) ** 0.94 (0.74-1.19) 1.01 (0.92-1.12) 1.09 (1.00-1.19) * 1.02 (0.88-1.18) 1.01 (0.87-1.18) 
       
Diabetes (Y vs N) 1.18 (1.10-1.28) ** 1.16 (0.77-1.76) 1.21 (1.04-1.41) * 1.32 (1.17-1.49) ** 0.96 (0.77-1.19) 1.02 (0.81-1.28) 
       
APOE Genotype (Y vs N) 2.87 (2.69-3.06) ** 3.06 (2.18-4.30) ** 3.28 (2.87-3.74) ** 3.64 (3.27-4.04) ** 2.92 (2.45-3.47) ** 2.02 (1.69-2.41) ** 
  
  p-value; * = <0.05 and ** = <0.001. Y= Yes, N = No 
Birth Cohort 1 (born 1896-1918) = The period leading up and through the end of WWI, Birth Cohort 2 (born 1919-1928) = Post WWI/the Roaring 20s, Birth Cohort 3 (born 
1929-1940) = Great Depression/Pre WWII, Birth Cohort 4 (born 1941-1945) = WWII, Birth Cohort 5 (born 1946-1955) = Baby Boom Cohort 
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Table 4: Adjusted Multivariate Logistic Regression Analysis of Individual Risk factors for Cognitive Impairment and Alzheimer’s Disease. 
 
 
Variables 
All Participants 
(n 22,952) 
Birth Cohort 1 
1,209 (5.27 %) 
Birth Cohort 2 
6,943 (30.25 %) 
Birth Cohort 3 
8,759 (38.16 %) 
 
Birth Cohort 4 
2,999 (13.07 %) 
Birth Cohort 5 
3,042 (13.25 %) 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
      
Age 1.03 (1.03-1.04) ** 0.99 (0.91-1.07) 1.02 (1.00-1.05) 1.08 (1.06-1.10) ** 1.04 (1.00-1.08) 0.96 (0.92-0.99) * 
       
Education 0.89 (0.88-0.91) ** 0.93 (0.87-0.99) * 0.89 (0.87-0.91) ** 0.89 (0.87-0.91) ** 0.89 (0.86-0.93) ** 0.88 (0.84-0.92) ** 
       
Pack-years of smoking 1.01 (0.99-1.03) 1.03 (0.94-1.13) 1.01 (0.98-1.04) 1.01 (0.98-1.04) 1.01 (0.96-1.07) 0.98 (0.91-1.04) 
       
Active smoking (Y vs N) 1.06 (0.91-1.23) 1.07 (0.40-2.86) 1.05 (0.76-1.47) 0.94 (0.74-1.21) 1.33 (0.94-1.89) 1.08 (0.76-1.53) 
       
Gender (M vs F) 1.89 (1.73-2.06) ** 1.84 (1.21-2.81) * 1.85 (1.57-2.18) ** 1.96 (1.71-2.25) ** 1.96 (1.56-2.47) ** 1.58 (1.23-2.03 * 
       
Race       
African American vs Whites 0.85 (0.75-0.97) * - 0.95 (0.73-1.22) 0.92 (0.76-1.11) 0.66 (0.47-0.93) * 0.69 (0.48-0.99) * 
Others vs Whites 1.31 (1.02-1.68) * 1.38 (0.56-3.40) 1.56 (0.94-2.61 1.20 (0.80-1.79) 0.92 (0.50-1.67) 1.38 (0.74-2.58) 
       
Hypertension (Y vs N) 0.99 (0.91-1.08) 0.93 (0.61-1.42) 1.01 (0.85-1.19) 0.92 (0.80-1.06) 1.12 (0.89-1.42) 1.04 (0.80-1.37) 
       
Diabetes (Y vs N) 0.97 (0.85-1.10) 0.80 (0.38-1.70) 0.94 (0.72-1.21) 1.09 (0.90-1.32) 0.72 (0.50-1.03) 0.99 (0.68-1.46) 
   
  p-value; * = <0.05 and ** = <0.001. Y= Yes, N = No 
Birth Cohort 1 (born 1896-1918) = The period leading up and through the end of WWI, Birth Cohort 2 (born 1919-1928) = Post WWI/the Roaring 20s, Birth Cohort 3 (born 
1929-1940) = Great Depression/Pre WWII, Birth Cohort 4 (born 1941-1945) = WWII, Birth Cohort 5 (born 1946-1955) = Baby Boom Cohort 
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Table 5: Sensitivity Analysis: 
Adjusted Multivariate Logistic Regression Analysis using APOE as an additional risk factor for Cognitive Impairment and Alzheimer’s Disease. 
 
 
 
Variables 
All Participants 
(n 22,952) 
Birth Cohort 1 
1,209 (5.27 %) 
Birth Cohort 2 
6,943 (30.25 %) 
Birth Cohort 3 
8,759 (38.16 %) 
 
Birth Cohort 4 
2,999 (13.07 %) 
Birth Cohort 5 
3,042 (13.25 %) 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
      
Age 1.04 (1.03-1.04) ** 0.99 (0.90-1.09) 1.04 (1.01-1.07) * 1.10 (1.08-1.13) ** 1.06 (1.01-1.12) * 0.98 (0.94-1.03) 
       
Education 0.89 (0.88-0.91) ** 0.94 (0.87-1.01) 0.88 (0.85-0.90) ** 0.90 (0.88-0.93) ** 0.89 (0.85-0.93) ** 0.88 (0.83-0.93) ** 
       
Pack-years of smoking 1.01 (0.99-1.04) 1.02 (0.91-1.14) 1.00 (0.96-1.04) 1.04 (1.00-1.07) 1.02 (0.95-1.09) 0.98 (0.91-1.06) 
       
Active smoking (Y vs N) 1.00 (0.83-1.20) 0.79 (0.25-2.43) 0.78 (0.52-1.18) 0.92 (0.67-1.26 1.54 (1.01-2.36) * 0.94 (0.62-1.44) 
       
Gender (M vs F) 2.10 (1.89-2.34) ** 2.28 (1.39-3.72) * 2.08 (1.70-2.54) ** 2.19 (1.85-2.60) ** 2.33 (1.75-3.09) ** 1.61 (1.18-2.19) * 
       
Race       
African American vs White 0.86 (0.72-1.01) - 1.11 (0.78-1.56) 0.95 (0.74-1.22) 0.52 (0.33-0.79) * 0.68 (0.41-1.11) 
Others vs White 1.46 (1.03-2.07) * 2.63 (0.44-15.72) 2.25 (0.99-5.12) 1.36 (0.76-2.43) 1.01 (0.47-2.21) 1.28 (0.60-2.73) 
       
Hypertension (Y vs N) 1.11 (1.00-1.24) 0.93 (0.57-1.52) 1.14 (0.93-1.39) 1.07 (0.90-1.27) 1.17 (0.88-1.56) 1.22 (0.86-1.71) 
       
Diabetes (Y vs N) 0.96 (0.82-1.13) 0.65 (0.26-1.62) 0.98 (0.70-1.36) 1.08 (0.84-1.38) 0.85 (0.54-1.34) 0.81 (0.48-1.35) 
       
APOE Genotype (Y vs N) 3.31 (2.97-3.69) ** 3.11 (1.66-5.84) * 3.26 (2.64-4.03) ** 3.88 (3.27-4.60) ** 3.46 (2.61-4.58) ** 2.20 (1.62-3.00) ** 
 
  p-value; * = <0.05 and ** = <0.001. Y= Yes, N = No 
Birth Cohort 1 (born 1896-1918) = The period leading up and through the end of WWI, Birth Cohort 2 (born 1919-1928) = Post WWI/the Roaring 20s, Birth Cohort 3 (born 
1929-1940) = Great Depression/Pre WWII, Birth Cohort 4 (born 1941-1945) = WWII, Birth Cohort 5 (born 1946-1955) = Baby Boom Cohort 
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Table 6: Secondary Analysis on Women regarding number of children: 
Adjusted Multivariate Logistic Regression Analysis using number of children as an additional risk factor for Cognitive Impairment and Alzheimer’s Disease in 
Women. 
 
 
Variables 
All Participants 
(n 13,713) 
Birth Cohort 1 
773 (5.64 %) 
Birth Cohort 2 
3,964 (28.91 %) 
Birth Cohort 3 
5,179 (37.77 %) 
Birth Cohort 4 
1,865 (13.60 %) 
Birth Cohort 5 
1,932 (14.09 %) 
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
       
Age 1.03 (1.02-1.04) ** 1.03 (0.92-1.16) 1.01 (0.98-1.04) 1.07 (1.04-1.10) ** 1.08 (1.02-1.14) * 0.97 (0.93-1.02) 
       
Education 0.89 (0.87-0.91) ** 0.88 (0.79-0.97) * 0.87 (0.84-0.90) ** 0.90 (0.87-0.93) ** 0.87 (0.82-0.92) ** 0.88 (0.83-0.94) * 
       
Number of Children 1.07 (1.03-1.11) * 1.10 (0.92-1.31) 1.05 (0.99-1.11) 1.10 (1.04-1.16) * 0.95 (0.85-1.06 1.07 (0.94-1.23) 
       
Pack-years of smoking 1.02 (0.99-1.05) 1.07 (0.93-1.24) 1.03 (0.98-1.08) 1.04 (1.00-1.09) 0.99 (0.92-1.07) 0.94 (0.85-1.03) 
       
Active smoking (Y vs N) 1.14 (0.94-1.39) 0.64 (0.20-2.06) 0.81 (0.53-1.26) 1.06 (0.78-1.46) 1.85 (1.18-2.89) * 1.47 (0.91-2.39) 
       
Race       
African American vs Whites 0.94 (0.80-1.10) - 1.01 (0.73-1.39) 1.00 (0.78-1.28) 0.65 (0.42-1.02) 0.82 (0.51-1.32) 
Others vs Whites 1.28 (0.89-1.84) 2.03 (0.53-7.74) 1.65 (0.75-3.67) 1.44 (0.78-2.64) 0.81 (0.37-1.75) 1.02 (0.39-2.65) 
       
Hypertension (Y vs N) 0.98 (0.87-1.11) 0.81 (0.44-1.50) 0.94 (0.74-1.19) 0.96 (0.79-1.17) 1.14 (0.83-1.58) 1.09 (0.75-1.59) 
       
Diabetes (Y vs N) 0.93 (0.77-1.12) 0.63 (0.17-2.34) 0.89 (0.61-1.31) 1.06 0.80-1.39) 0.71 (0.42-1.17) 0.92 (0.53-1.61) 
 
  p-value; * = <0.05 and ** = <0.001. Y= Yes, N = No 
Birth Cohort 1 (born 1896-1918) = The period leading up and through the end of WWI, Birth Cohort 2 (born 1919-1928) = Post WWI/the Roaring 20s, Birth Cohort 3 (born 
1929-1940) = Great Depression/Pre WWII, Birth Cohort 4 (born 1941-1945) = WWII, Birth Cohort 5 (born 1946-1955) = Baby Boom Cohort 
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Table 7: Secondary Analysis on Women regarding Number of Children: 
Adjusted Multivariate Logistic Regression Analysis adding APOE in addition to number of children variables as additional risk factors for Cognitive Impairment 
and Alzheimer’s Disease in Women. 
 
 
Variables 
All Participants 
(n 13,713) 
Birth Cohort 1 
773 (5.64 %) 
Birth Cohort 2 
3,964 (28.91 %) 
Birth Cohort 3 
5,179 (37.77 %) 
Birth Cohort 4 
1,865 (13.60 %) 
Birth Cohort 5 
1,932 (14.09 %) 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
       
Age 1.03 (1.03-1.04) ** 1.09 (0.96-1.24) 1.02 (0.98-1.07) 1.09 (1.06-1.13) ** 1.08 (1.01-1.17) * 1.00 (0.93-1.06) 
       
Education 0.88 (0.85-0.90) ** 0.86 (0.75-0.98) * 0.84 (0.80-0.88) ** 0.90 (0.86-0.93) ** 0.87 (0.81-0.93) ** 0.86 (0.79-0.94) * 
       
Number of Children 1.06 (1.02-1.11) * 1.06 (0.85-1.32) 1.06 (0.98-1.13) 1.08 (1.01-1.16) * 1.02 (0.88-1.18) 1.01 (0.85-1.21) 
       
Pack-years of smoking 1.02 (0.99-1.06 1.03 (0.86-1.23) 1.02 (0.96-1.08) 1.07 (1.01-1.12) * 0.99 (0.90-1.09) 0.91 (0.81-1.02) 
       
Active smoking (Y vs N) 1.07 (0.84-1.37) 0.46 (0.11-1.89) 0.61 (0.35-1.06) 1.09 (0.73-1.62) 1.90 (1.10-3.27) * 1.29 (0.71-2.35) 
       
Race       
African American vs Whites 0.97 (0.78-1.19) - 1.19 (0.78-1.82) 1.00 (0.73-1.38) 0.63 (0.36-1.10) 0.78 (0.41-1.51) 
Others vs Whites 1.56 (0.94-2.60) 2.44 (0.14-43.48) 2.55 (0.77-8.41) 1.76 (0.71-4.39) 1.14 (0.38-3.43) 0.94 (0.30-2.97) 
       
Hypertension (Y vs N) 1.12 (0.96-1.30) 0.62 (0.30-1.28) 1.01 (0.76-1.35) 1.24 (0.97-1.59) 1.06 (0.71-1.58) 1.53 (0.95-2.47) 
       
Diabetes (Y vs N) 0.87 (0.68-1.10) 0.69 (0.14-3.51) 0.97 (0.59-1.59) 0.85 (0.60-1.22) 0.79 (0.41-1.51) 0.79 (0.37-1.66) 
       
APOE Genotype (Y vs N) 3.49 (3.00-4.05) ** 4.42 (1.66-11.78) * 3.15 (2.34-4.24) ** 4.35 (3.44-5.51) ** 3.68 (2.52-5.39) ** 2.41 (1.56-3.72) ** 
 
  p-value; * = <0.05 and ** = <0.001. Y= Yes, N = No 
Birth Cohort 1 (born 1896-1918) = The period leading up and through the end of WWI, Birth Cohort 2 (born 1919-1928) = Post WWI/the Roaring 20s, Birth Cohort 3 (born 
1929-1940) = Great Depression/Pre WWII, Birth Cohort 4 (born 1941-1945) = WWII, Birth Cohort 5 (born 1946-1955) = Baby Boom Cohort 
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